Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification

Somatic ERBB2 amplification or activating mutations occur in approximately 2–5% of metastatic colorectal adenocarcinomas and are presumed to be oncogenic drivers, but limited evidence exists to suggest these lesions are sensitive to targeted monotherapy in patients. Here we present the case of a pat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoscience
Hauptverfasser: Disel, Umut, Germain, Alexis, Yilmazel, Bahar, Abali, Huseyin, Bolat, Filiz Aka, Yelensky, Roman, Elvin, Julia A., Lipson, Doron, Chmielecki, Juliann, Wang, Kai, Stephens, Philip J., Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., George, Thomas J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2015
Schlagworte:
Case Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4506361/
https://ncbi.nlm.nih.gov/pubmed/26244165
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge